Business · 01/06/2000Updated: 10/17/2026 · 1 min read

FDA Expands Clinical Hold Rule for Investigational New Drugs for Life-Threatening Diseases

Summary

The FDA is updating its regulations to allow for clinical holds on studies for life-threatening diseases, with a focus on protecting women with reproductive potential from potential risks associated with investigational drugs.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 9/17/2026

FDA Grants Partial Exemption to Medical Devices

The FDA has finalized a rule exempting certain radiology computer-aided detection and diagnosis devices from premarket notification requirements, following a petition filed in 2025 and denied in 2026.

Read summary →

Business · 9/16/2026

Government-Owned Inventions; Availability for Licensing

The National Institute of Allergy and Infectious Diseases (NIAID) is giving notice of a government-owned invention available for licensing to achieve commercialization of federally funded research results.

Read summary →

Business · 9/16/2026

Medicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Level II Coding

The Centers for Medicare and Medicaid Services (CMS) will hold its second biannual Healthcare Common Procedure Coding System (HCPCS) Level II public meeting of 2026 to discuss new revisions to the HCPCS Level II code set for non-drug and non-biological items and services.

Read summary →

Business · 9/15/2026

FDA Establishes Public Docket for Rare Disease Clinical Investigations Statistical Considerations

The FDA is collecting feedback on statistical considerations for rare disease clinical investigations through a public docket, which is open until a certain date, and a Rare Disease Innovation, Science, and Exploration (RISE) Workshop on the topic.

Read summary →

Business · 9/15/2026

World Trade Center Health Program Denies Stroke Petitions

The World Trade Center Health Program Administrator has denied petitions to add stroke to the list of WTC-related health conditions due to insufficient evidence, and therefore will not request a recommendation from the WTC Health Program Scientific/Technical Advisory Committee or publish a proposed rule.

Read summary →

Business · 9/15/2026

World Trade Center Health Program Petition for Peripheral Artery Disease Found Lacking in Evidence

The World Trade Center Health Program Administrator has denied a petition to add peripheral artery disease to the list of WTC-related health conditions due to insufficient evidence, and therefore will not request a recommendation from the WTC Health Program Scientific/Technical Advisory Committee or publish a proposed rule.

Read summary →